The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Nikonov E.L.

Pirogov Russian National Research Medical University

Zhuravleva M.V.

I.M. Sechenov First Moscow State Medical University (Sechenov University);
Scientific Centre of Medical Application Expertise of the Ministry of the Healthcare of the Russian Federation

Zharova M.E.

Pirogov Russian National Research Medical University;
Central Clinical Hospital with Polyclinic of Administrative Directorate of the President of the Russian Federation

Gorelov M.V.

Russian National Research Medical University named after Pirogov of the Ministry of Health of Russia

Hydroxychloroquine: the story of one drug during the COVID-19 pandemic

Authors:

Nikonov E.L., Zhuravleva M.V., Zharova M.E., Gorelov M.V.

More about the authors

Journal: Russian Journal of Preventive Medicine. 2020;23(8): 74‑82

DOI: 10.17116/profmed20202308174

Views: 962

Downloaded: 25

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

Nikonov EL, Zhuravleva MV, Zharova ME, Gorelov MV. Hydroxychloroquine: the story of one drug during the COVID-19 pandemic. Russian Journal of Preventive Medicine. 2020;23(8):74‑82. (In Russ.)
https://doi.org/10.17116/profmed20202308174

 
МСФ на ЯМ
Close metadata
Recommended articles:
Causes of hospital mortality in adults based on medi­cal certificates of death. Russian Journal of Preventive Medi­cine. 2024;(3):7-13
Anti­biotic resi­stance of the upper respiratory tract microbiota in children with the new coro­navirus infe­ction in Ryazan. Russian Journal of Preventive Medi­cine. 2024;(3):45-51
Variability of death rates from respiratory diseases in the regions of the Russian Fede­ration during the COVID-19 pandemic and the three previous years. Russian Journal of Preventive Medi­cine. 2024;(4):82-88
A clinical case of the new-onset bipo­lar affe­ctive diso­rder in the postcovid period. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3):125-129
Comparison of the clinical performance of immu­nochromatographic tests for the dete­ction of SARS-CoV-2 anti­gens with data from inde­pendent studies. Labo­ratory Service. 2024;(1):13-19
Adve­rse peri­natal outcomes in COVID-19. Analysis of a series of clinical obse­rvations. Russian Bulletin of Obstetrician-Gynecologist. 2024;(2):86-90
Staging of COVID-19 morphological mani­festations in lungs depe­nding on disease dura­tion. Fore­nsic Medi­cal Expe­rtise. 2024;(2):28-31
Russian COVID-19 vaccines as a risk factor of myopericarditis in patients with or without previous infe­ction. Russian Journal of Cardiology and Cardiovascular Surgery. 2024;(2):184-193
Exosomes’ role in inte­rcellular inte­ractions in different variants of lung injury in fatal cases of COVID-19. Russian Journal of Archive of Pathology. 2024;(2):22-29
Age features of immu­nity to SARS-CoV-2 of metropolis popu­lation in the dyna­mics. Russian Journal of Clinical Dermatology and Vene­reology. 2024;(2):118-128

The new coronavirus (SARS-CoV-2) poses a serious threat to public health worldwide. From the moment of its finding to the present, the incidence of new cases is only increasing. So far, no drugs were proven to have antiviral activity in clinical practice. Many drugs have already gone a path from in vitro studies to randomized clinical trials in vivo.

OBJECTIVE

To review the literature on the use of hydroxychloroquine for the prevention and treatment of new coronavirus infection (COVID-19) for the period from the date of use until June 2020.

Keywords:

COVID-19
coronavirus
SARS-CoV-2
hydroxychloroquine

Authors:

Nikonov E.L.

Pirogov Russian National Research Medical University

Zhuravleva M.V.

I.M. Sechenov First Moscow State Medical University (Sechenov University);
Scientific Centre of Medical Application Expertise of the Ministry of the Healthcare of the Russian Federation

Zharova M.E.

Pirogov Russian National Research Medical University;
Central Clinical Hospital with Polyclinic of Administrative Directorate of the President of the Russian Federation

Gorelov M.V.

Russian National Research Medical University named after Pirogov of the Ministry of Health of Russia

Received:

26.06.2020

Accepted:

12.10.2020

List of references:

  1. Ben-Zvi I, Kivity S, Langevitz P, Shoenfeld Y. Hydroxychloroquine: from malaria to autoimmunity. Clinical Reviews in Allergy & Immunology. 2012; 42(2):145-153.  https://doi.org/10.1007/s12016-010-8243-x
  2. Mullins JF, Watts FL, Wilson CJ. Plaquenil in the treatment of lupus erythematosus. Journal of the American Medical Association. 1956;161(9):879-881.  https://doi.org/10.1001/jama.1956.62970090020017k
  3. Wallace D, Hahn B. Dubois’ Lupus Erythematosus and Related Syndromes. 8th ed. Saunders; 2020.
  4. Inglot AD. Comparison of the antiviral activity in vitro of some non-steroidal anti-inflammatory drugs. The Journal of General Virology. 1969;4(2):203-214.  https://doi.org/10.1099/0022-1317-4-2-203
  5. Gothberg LA. Severe infectious mononucleosis treated with chloroquine phosphate. Journal of the American Medical Association. 1960;173:53-57.  https://doi.org/10.1001/jama.1960.73020190016012
  6. Rolain JM, Colson P, Raoult D. Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century. International Journal of Antimicrobial Agents. 2007;30(4):297-308.  https://doi.org/10.1016/j.ijantimicag.2007.05.015
  7. Sperber K, Kalb TH, Stecher VJ, Banerjee R, Mayer L. Inhibition of human immunodeficiency virus type 1 replication by hydroxychloroquine in T cells and monocytes. AIDS Research and Human Retroviruses. 1993;9(1):91-98.  https://doi.org/10.1089/aid.1993.9.91
  8. Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today’s diseases? The Lancet. Infectious diseases. 2003;3(11):722-727.  https://doi.org/10.1016/s1473-3099(03)00806-5
  9. Savarino A, Di Trani L, Donatelli I, Cauda R, Cassone A. New insights into the antiviral effects of chloroquine. The Lancet. Infectious diseases. 2006; 6(2):67-69.  https://doi.org/10.1016/S1473-3099(06)70361-9
  10. Devaux CA, Rolain JM, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? International Journal of Antimicrobial Agents. 2020;105938. https://doi.org/10.1016/j.ijantimicag.2020.105938
  11. Keyaerts E, Vijgen L, Maes P, Neyts J, Van Ranst M. In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochemical and biophysical research communications. 2004;323(1):264-268.  https://doi.org/10.1016/j.bbrc.2004.08.085
  12. Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, Seidah NG, Nichol ST. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virology Journal. 2005;2:69.  https://doi.org/10.1186/1743-422X-2-69
  13. de Wilde AH, Jochmans D, Posthuma CC, Zevenhoven-Dobbe JC, van Nieuwkoop S, Bestebroer TM, van den Hoogen BG, Neyts J, Snijder EJ. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrobial Agents and Chemotherapy. 2014;58(8):4875-4884. https://doi.org/10.1128/AAC.03011-14
  14. Dyall J, Coleman CM, Hart BJ, Venkataraman T, Holbrook MR, Kindrachuk J, Johnson RF, Olinger GG, Jahrling PB, Laidlaw M, Johansen LM, Lear-Rooney CM, Glass PJ, Hensley LE, Frieman MB. Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrobial Agents and Chemotherapy. 2014;58(8): 4885-4893. https://doi.org/10.1128/AAC.03036-14
  15. Li X, Zai J, Zhao Q, Nie Q, Li Y, Foley BT, Chaillon A. Evolutionary history, potential intermediate animal host, and cross-species analyses of SARS-CoV-2. Journal of Medical Virology. 2020;92(6):602-611.  https://doi.org/10.1002/jmv.25731
  16. Wén X. Wuhan CDC confirm: pneumonia infections of unknown cause has appeared in the local area, the number of infected people is being calculated. Beijing News Online. (In Chinese). Accessed May 18, 2020. https://www.bjnews.com.cn/news/2019/12/31/668430.html
  17. WHO. Timeline — COVID-19. Geneva: WHO; 2020. Accessed May 18, 2020. https://www.who.int/news-room/detail/27-04-2020-who-timeline---covid-19
  18. Informacionnoe agentstvo Rossii «TASS». V Rossii vyyavili pervye dva sluchaya zarazheniya, 31 yanvarya 2020 g. M.: TASS; 2020. Accessed May 18, 2020. (In Russ.). https://tass.ru/obschestvo/7656549.
  19. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Research. 2020;30(3):269-271.  https://doi.org/10.1038/s41422-020-0282-0
  20. Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Bioscience Trends. 2020;14(1):72-73.  https://doi.org/10.5582/bst.2020.01047
  21. Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, Liu X, Zhao L, Dong E, Song C, Zhan S, Lu R, Li H, Tan W, Liu D. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clinical Infectious Diseases. 2020:ciaa237. https://doi.org/10.1093/cid/ciaa237
  22. Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, Li Y, Hu Z, Zhong W, Wang M. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discovery. 2020;6(1):16.  https://doi.org/10.1038/s41421-020-0156-0
  23. Chen J, Liu Da, Liu L, Liu P, Xu Q, Xia L, Ling Y, Huang D, Song S, Zhang D, Qian Z, Li T, Shen Y, Lu H. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19). Journal Zhejiang Univercity (Med Sci). 2020;49(1):215-219.  https://doi.org/10.3785/j.issn.1008-9292.2020.03.03
  24. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, Doudier B, Courjon J, Giordanengo V, Vieira VE, Dupont HT, Honoré S, Colson P, Chabrière E, La Scola B, Rolain JM, Brouqui P, Raoult D. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International Journal of Antimicrobial Agents. 2020;105949. https://doi.org/10.1016/j.ijantimicag.2020.105949
  25. FDA authorizes widespread use of unproven drugs to treat coronavirus, saying possible benefit outweighs risk. Accessed May 18, 2020. https://www.washingtonpost.com/business/2020/03/30/coronavirus-drugs-hydroxychloroquin-chloroquine/
  26. Vremennye metodicheskie rekomendacii Ministerstva Zdravoohraneniya RF. Profilaktika, diagnostika i lechenie novoj koronavirusnoj infekcii (COVID-19). Versiya ot 27.03.20. Accessed April 20, 2020. (In Russ.). https://static-1.rosminzdrav.ru/system/attachments/attaches/000/049/951/original/09042020_%D0%9C%D0%A0_COVID-19_v5.pdf
  27. Molina JM, Delaugerre C, Le Goff J, Mela-Lima B, Ponscarme D, Goldwirt L, de Castro N. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Medecine et Maladies Infectieuses. 2020;50(4):384.  https://doi.org/10.1016/j.medmal.2020.03.006
  28. Chen Z, Hu J, Zhang Z, Jiang S, Han S, Yan D, Zhuang R, Hu B, Zhang Z. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. medRxiv. 2020;2020.03.22.20040758. https://doi.org/10.1101/2020.03.22.20040758
  29. Carlson R. Doctors Rate Hydroxychloroquine Most Effective Therapy for Coronavirus Infection. Accessed May 18, 2020. https://www.precisionvaccinations.com/fda-issued-emergency-authorization-hydroxychloroquine-treatment-covid-19-patients-usa
  30. Perinel S, Launay M, Botelho-Nevers É, Diconne É, Louf-Durier A, Lachand R, Murgier M, Page D, Vermesch R, Thierry G, Delavenne X. Towards Optimization of Hydroxychloroquine Dosing in Intensive Care Unit COVID-19 Patients. Clinical Infectious Diseases. 2020;ciaa394. https://doi.org/10.1093/cid/ciaa394
  31. Arnold SLM, Buckner F. Hydroxychloroquine for Treatment of SARS-CoV-2 Infection? Improving Our Confidence in a Model-Based Approach to Dose Selection. Clinical and Translational Science. 2020;10.1111/cts.12797. https://doi.org/10.1111/cts.12797
  32. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Sevestre J, Mailhe M, Doudier B, Aubry C, Amrane S, Seng P, Hocquart M, Eldin C, Finance J, Vieira VE, Tissot-Dupont HT, Honoré S, Stein A, Million M, Colson P, La Scola B, Veit V, Jacquier A, Deharo JC, Drancourt M, Fournier PE, Rolain JM, Brouqui P, Raoult D. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study. Travel Medicine and Infectious Disease. 2020;34:101663. https://doi.org/10.1016/j.tmaid.2020.101663
  33. Mahevas M, Tran V, Roumier M, Chabrol A, Paule R, Guillaud C, Gallien S, Lepeule R, Szwebel TA, Lescure X, Schlemmer F, Matignon M, Khellaf M, Crickx E, Terrier B, Morbieu C, Legendre P, Dang J, Schoindre Y, Pawlotski JM, Michel M, Perrodeau E, Carlier N, Roche N, De Lastours V, Mouthon L, Audureau E, Ravaud P, Godeau B, Costedoat N. No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial. medRxiv. 2020;2020.04.10.20060699. https://doi.org/10.1101/2020.04.10.20060699
  34. Rasporyazhenie Pravitel’stva Rossijskoj Federacii ot 16.04.20 №1030-r. Accessed April 20, 2020. (In Russ.). https://publication.pravo.gov.ru/Document/View/0001202004160037
  35. Magagnoli J, Narendran S, Pereira F, Cummings T, Hardin JW, Sutton SS, Ambati J. Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19. medRxiv. 2020;2020.04.16.20065920. https://doi.org/10.1016/j.medj.2020.06.001
  36. Mercuro NJ, Yen CF, Shim DJ, Maher TR, McCoy CM, Zimetbaum PJ, Gold HS. Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19). JAMA Cardiology. 2020;e201834. https://doi.org/10.1001/jamacardio.2020.1834
  37. Bessière F, Roccia H, Delinière A, Charrière R, Chevalier P, Argaud L, Cour M. Assessment of QT Intervals in a Case Series of Patients With Coronavirus Disease 2019 (COVID-19) Infection Treated With Hydroxychloroquine Alone or in Combination With Azithromycin in an Intensive Care Unit. JAMA Cardiology. 2020;e201787. https://doi.org/10.1001/jamacardio.2020.1787
  38. Yu B, Wang DW, Li C. Hydroxychloroquine application is associated with a decreased mortality in critically ill patients with COVID-19. medRxiv. 2020: 2020.04.27.20073379. https://doi.org/10.1101/2020.04.27.20073379
  39. Huang M, Li M, Xiao F, Liang J, Pang P, Tang T, Liu S, Chen B, Shu J, You Y, Li Y, Tang M, Zhou J, Jiang G, Xiang J, Hong W, He S, Wang Z, Feng J, Lin J, Ye Y, Wu Z, Li Y, Zhong B, Sun R, Hong Z, Liu J, Chen H, Wang X, Li Z, Pei D, Tian L, Xia J, Jiang S, Zhong N, Shan H. Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19. medRxiv. 2020:2020. 04.26.20081059. https://doi.org/10.1101/2020.04.26.20081059
  40. Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W, Wu Y, Xiao W, Liu S, Chen E, Chen W, Wang X, Yang J, Lin J, Zhao Q, Yan Y, Xie Z, Li D, Yang Y, Liu L, Qu J, Ning G, Shi G, Xie Q. Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial. medRxiv. 2020: 2020.04.10.20060558. https://doi.org/10.1101/2020.04.10.20060558
  41. Membrillo FJ, Ramírez-Olivencia G, Estébanez M, de Dios B, Herrero MD, Mata T, Borobia AM, Gutiérrez C, Simón M, Ochoa A, Martínez Y, Aguirre A, Alcántara FDA, Fernández-González P, López E, Valle P, Campos S, Navarro M, Ballester LE. Early Hydroxychloroquine Is Associated with an Increase of Survival in COVID-19 Patients: An Observational Study. Preprints. 2020:2020050057. https://doi.org/10.20944/preprints202005.0057.v2
  42. Million M, Lagier JC, Gautret P, Colson P, Fournier PE, Amrane S, Hocquart M, Mailhe M, Esteves-Vieira V, Doudier B, Aubry C, Correard F, Giraud-Gatineau A, Roussel Y, Berenger C, Cassir N, Seng P, Zandotti C, Dhiver C, Ravaux I, Tomei C, Eldin C, Tissot-Dupont H, Honoré S, Stein A, Jacquier A, Deharo JC, Chabrière E, Levasseur A, Fenollar F, Rolain JM, Obadia Y, Brouqui P, Drancourt M, La Scola B, Parola P, Raoult D. Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France. Travel Medicine and Infectious Disease. 2020;101738. https://doi.org/10.1016/j.tmaid.2020.101738
  43. Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G, Labella A, Manson DK, Kubin C, Barr RG, Sobieszczyk ME, Schluger NW. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. New England Journal of Medicine. 2020;382(25):2411-2418. https://doi.org/10.1056/NEJMoa2012410
  44. Rosenberg ES, Dufort EM, Udo T, Wilberschied LA, Kumar J, Tesoriero J, Weinberg P, Kirkwood J, Muse A, DeHovitz J, Blog DS, Hutton B, Holtgrave DR, Zucker HA. Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State. Journal of the American Medical Association. 2020;323(24): 2493-2502. https://doi.org/10.1001/jama.2020.8630
  45. Carlucci P, Ahuja T, Petrilli CM, Rajagopalan H, Jones S, Rahimian J. Hydroxychloroquine and azithromycin plus zinc vs hydroxychloroquine and azithromycin alone: outcomes in hospitalized COVID-19 patients. medRxiv. 2020:2020.05.02.20080036. https://doi.org/10.1101/2020.05.02.20080036
  46. Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W, Wu Y, Xiao W, Liu S, Chen E, Chen W, Wang X, Yang J, Lin J, Zhao Q, Yan Y, Xie Z, Li D, Yang Y, Liu L, Qu J, Ning G, Shi G, Xie Q. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ. 2020;369:m1849. https://doi.org/10.1136/bmj.m1849
  47. Paule R, Guillaud C, Fois E, Lepeule R, Szwebel TA, Lescure FX, Schlemmer F, Matignon M, Khellaf M, Crickx E, Terrier B, Morbieu C, Legendre P, Dang J, Schoindre Y, Pawlotsky JM, Michel M, Perrodeau E, Carlier N, Roche N, de Lastours V, Ourghanlian C, Kerneis S, Ménager P, Mouthon L, Audureau E, Ravaud P, Godeau B, Gallien S, Costedoat-Chalumeau N. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. BMJ. 2020;369:m1844. https://doi.org/10.1136/bmj.m1844
  48. Early diagnosis and management of COVID-19 patients: a real-life cohort study of 3,737 patients, Marseille, France. Accessed April 20, 2020. https://www.mediterranee-infection.com/early-diagnosis-and-management-of-covid-19-patients-a-real-life-cohort-study-of-3737-patients-marseille-france/
  49. Chacko J, Brar G, Premkumar R. Hydroxychloroquine in COVID-19: A systematic review and meta-analysis. medRxiv. 2020:2020.05.14.20101774. https://doi.org/10.1101/2020.05.14.20101774
  50. Shamshirian A, Hessami A, Heydari K, Alizadeh-Navaei R, Ebrahimzadeh MA, YIP GW, Ghasemian R, Sedaghat M, Baradaran H, Yazdi SM, Aboufazeli E, Jafarpour H, Dadgostar E, Tirandazi B, Karimifar K, Eftekhari A, Shamshirianet D. Hydroxychloroquine Versus COVID-19: A Periodic Systematic Review and Meta-Analysis. medRxiv. 2020:2020.04.14. 20065276. https://doi.org/10.1101/2020.04.14.20065276
  51. Mehra MR, Desai SS, Ruschitzka F, Patel AN. RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet. 2020;S0140-6736(20)31180-6.  https://doi.org/10.1016/S0140-6736(20)31180-6
  52. World Health Organization. Hydroxychloroquine and COVID-19. Geneva: WHO; 2020. Accessed June 18, 2020. https://www.who.int/news-room/q-a-detail/q-a-hydroxychloroquine-and-covid-19
  53. Watson J. An open letter to Mehra et al and The Lancet. Accessed June 18, 2020. https://zenodo.org/record/3862789/files/Open Letter the statistical analysis and data integrity of Mehra et al_Final.pdf.
  54. Lancet, NEJM retract controversial COVID-19 studies based on Surgisphere data. Accessed June 18, 2020. https://retractionwatch.com/2020/06/04/lancet-retracts-controversial-hydroxychloroquine-study/
  55. Horby P, Landray M. No clinical benefit from use of hydroxychloroquine in hospitalised patients with COVID-19. Accessed June 18, 2020. https://www.recoverytrial.net/files/hcq-recovery-statement-050620-final-002.pdf
  56. Howard J. CNN. FDA revokes authorization of drug Trump touted. Accessed June 18, 2020. https://edition.cnn.com/2020/06/15/politics/fda-hydroxychloroquine-coronavirus/index.html
  57. Million M, Gautret P, Colson P, Roussel Y, Dubourg G, Chabriere E, Honore S, Rolain J-M, Fenollar F, Fournier P-E, Lagier J-C, Parola P, Brouqui P, Raoult D. Clinical Efficacy of Chloroquine derivatives in COVID-19 Infection: Comparative meta-analysis between the Big data and the real world. New Microbes and New Infections. 2020;100709. https://doi.org/10.1016/j.nmni.2020.100709
  58. Vremennye metodicheskie rekomendacii Ministerstva Zdravoohraneniya RF. Profilaktika, diagnostika i lechenie novoj koronavirusnoj infekcii (COVID-19). Versiya ot 03.06.20. Accessed June 10, 2020. (In Russ.). https://static-0.rosminzdrav.ru/system/attachments/attaches/000/050/584/original/03062020_%D0%9CR_COVID-19_v7.pdf
  59. Colson P, Rolain J-M, Lagier J-C, Brouqui P, Raoult D. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. International Journal of Antimicrobial Agents. 2020;105932. https://doi.org/10.1016/j.ijantimicag.2020.105932
  60. Colson P, Rolain JM, Raoult D. Chloroquine for the 2019 novel coronavirus SARS-CoV-2. International Journal of Antimicrobial Agents. 2020;55(3): 105923. https://doi.org/10.1016/j.ijantimicag.2020.105923
  61. Carlson. R. India Authorizes Hydroxy-Chloroquine For Coronavirus Infection Prevention. Accessed June 18, 2020. https://www.precisionvaccinations.com/hydroxy-chloroquine-approved-asymptomatic-household-contacts-laboratory-confirmed-covid-19-patients
  62. Prikaz Departamenta zdravoohraneniya Moskvy ot 30.03.20 №315 «O merah profilaktiki u sotrudnikov medicinskih organizacij gosudarstvennoj sistemy zdravoohraneniya goroda Moskvy, privlechennyh k realizacii meropriyatij po preduprezhdeniyu rasprostraneniya v gorode Moskve novoj koronavirusnoj infekcii (COVID-19)». Accessed June 16, 2020. (In Russ.). https://mosgorzdrav.ru/ru-RU/document/default/search.html?phrase=315&interval=&group_id=0
  63. Rathi S, Ish P, Kalantri A, Kalantri S. Hydroxychloroquine prophylaxis for COVID-19 contacts in India. The Lancet. Infectious Diseases. 2020;S1473-3099(20)30313-3.  https://doi.org/10.1016/S1473-3099(20)30313-3
  64. Tilangi P, Desai D, Khan A, Soneja M. Hydroxychloroquine prophylaxis for high-risk COVID-19 contacts in India: a prudent approach. The Lancet. Infectious Diseases. 2020;S1473-3099(20)30430-8.  https://doi.org/10.1016/S1473-3099(20)30430-8
  65. Lee SH, Son H, Peck KR. Can post-exposure prophylaxis for COVID-19 be considered as an outbreak response strategy in long-term care hospitals? International Journal of Antimicrobial Agents. 2020;55(6):105988. https://doi.org/10.1016/j.ijantimicag.2020.105988
  66. Bienvenu A-L, Marty AM, Jones MK, Picot S. Systematic review of registered trials of Hydroxychloroquine prophylaxis for COVID-19 health-care workers at the first third of 2020. One Health. 2020;10:100141. https://doi.org/10.1016/j.onehlt.2020.100141
  67. Cohen MS. Hydroxychloroquine for the Prevention of Covid-19 — Searching for Evidence. New England Journal of Medicine. 2020;S1473-3099(20) 30430-8.  https://doi.org/10.1056/NEJMe2020388
  68. Bhattacharya R, Chowdhury S, Mukherjee R, Nandi A, Kulshrestha M, Ghosh R, Saha S. Pre exposure Hydroxychloroquine use is associated with reduced COVID19 risk in healthcare workers. medRxiv. 2020:2020.06.09. 20116806. https://doi.org/10.1101/2020.06.09.20116806

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.